Available Trials
For detailed information about any of the following studies, please contact our Research Department at 352-732-4938.
CLINICAL TRIALS:
Lung Cancer
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
https://clinicaltrials.gov/ct2/show/NCT03906071
Double Blinded, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Canakinumab Vs Placebo as Adjuvant Therapy in Adult Subjects with Stages II-IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-Small Cell Lung Cancer (NSCLC)
https://www.clinicaltrials.gov/ct2/show/NCT03447769#contacts
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT04265534
Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer - Drugs: JNJ-61186372, Lazertinib, Pemetrexed, Carboplatin, JNJ-61186372 - EGFR and MET
https://clinicaltrials.gov/ct2/show/NCT02609776
Breast
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
https://www.clinicaltrials.gov/ct2/show/NCT04251533
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation - Drugs: Lasofoxifene, Fulvestrant - ESR1 mutations
https://clinicaltrials.gov/ct2/show/NCT03781063
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation - Drugs: Lasofoxifene and abemaciclib (VERZENIO).- ESR1 mutations
https://clinicaltrials.gov/ct2/show/NCT04432454
Solid Tumors
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04561362?term=BT8009-100&draw=2&rank=1
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab (Anti-PD-1) and/or mFOLFOX6 in Subjects with Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04306900
A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04485013
A phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusions Drugs: IDE196 - GNAQ or GNA11 mutations or PRKC fusions
https://clinicaltrials.gov/ct2/show/NCT03947385
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation - Drugs: MRTX849, Pembrolizumab, Cetuximab, Afatinib - KRAS G12C
https://clinicaltrials.gov/ct2/show/NCT03785249 Mutation
A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors - Drugs: Seribantumab - Neuregulin-1 (NRG1) Fusion
https://www.clinicaltrials.gov/ct2/show/NCT04383210
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors - Drugs: zenocutuzumab (MCLA-128) - Neuregulin-1 (NRG1) Fusion
https://clinicaltrials.gov/ct2/show/NCT02912949
A Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors - Drugs: APL-101 Oral Capsules - c-Met EXON 14 Skip Mutations c-Met Dysregulation
https://www.clinicaltrials.gov/ct2/show/NCT03175224
A Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Cancer - Drugs: Seribantumab - NRG1 Fusion
https://clinicaltrials.gov/ct2/show/NCT04383210
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations - FGFR
https://clinicaltrials.gov/ct2/show/NCT04083976
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements - Drugs: Oral repotrectinib (TPX-0005) - ROS1, or NTRK1-3 Rearrangements
https://clinicaltrials.gov/ct2/show/NCT03093116
B-Cell Lymphoma and Non-Hodgkin's Lymphoma
PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003) - Drugs: MT-3724 - CD20
https://clinicaltrials.gov/ct2/show/NCT03645395
PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma - Drugs: MT-3724 - CD20
https://clinicaltrials.gov/ct2/show/NCT03488251
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ - Drugs: Enzastaurin (Kinenza®), R-CHOP, Placebo - Positive for Genomic Biomarker DGM1
https://clinicaltrials.gov/ct2/show/NCT03263026
Unresectable or Metastatic Melanoma
Open-label, Active-controlled, Multicenter Phase II Study to Investigate the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma (UV1-202)
https://clinicaltrials.gov/ct2/show/NCT04382664
Prostate
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer - Drugs: Niraparib, Abiraterone Acetate, Prednisone, Placebo - BRCA 1/2 and CDK12
https://clinicaltrials.gov/ct2/show/NCT03748641
Gastric or Gastroesophageal Junction Cancer
A Phase 2/3 Trial to Evaluate Margetuximab in Combination with Chemotherapy and CPI or Trastuzumab and Chemotherapy alone in Patients with Treatment-naïve Metastatic or Locally Advanced, Her2-positive Gastric or Gastroesophageal Junction Cancer
https://clinicaltrials.gov/ct2/show/NCT04082364
Polycythemia Vera
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera
https://clinicaltrials.gov/ct2/show/NCT04057040
Primary Immune Thrombocytopenia (ITP)
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg IV in Adult Patients with ITP
https://clinicaltrials.gov/ct2/show/NCT04188379
Folicular Lymphoma
Double-blinded, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK), Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/study/NCT02947347
Supportive Care
A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg (ALOXI®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy
https://www.clinicaltrials.gov/ct2/show/NCT04592198
Targeted Therapy Trails
We have access to over 30 trials through Tempus’ and Caris PharmaTech’s Just-in-Time activation program. These trials can be activated within 2 weeks of identifying an eligible sub
